Lyra Therapeutics (LYRA) Change in Cash (2019 - 2025)

Lyra Therapeutics (LYRA) has reported Change in Cash for 7 consecutive years, with -$6.2 million the latest figure, recorded in Q4 2025.

• Change in Cash for Q4 2025 came in at -$6.2 million, down 136.73% year-over-year; the trailing twelve-month figure through Dec 2025 was -$24.7 million (down 231.12% YoY), and the FY2025 annual result was -$24.7 million, down 231.12% from the prior year.
• Change in Cash for Q4 2025 stood at -$6.2 million, up from -$7.7 million in the prior quarter.
• The five-year high for Change in Cash was $88.0 million in Q2 2022, with the low at -$77.0 million in Q4 2022.
• A 5-year average of -$2.9 million and a median of -$7.9 million in 2024 frame the typical range for Change in Cash.
• The widest YoY moves for Change in Cash: up 2892.28% in 2022, down 522.04% in 2022.
• Lyra Therapeutics' Change in Cash stood at -$12.4 million in 2021, then tumbled by 522.04% to -$77.0 million in 2022, then jumped by 96.76% to -$2.5 million in 2023, then surged by 771.93% to $16.8 million in 2024, then plunged by 136.73% to -$6.2 million in 2025.
• The last three Change in Cash figures came in at -$6.2 million (Q4 2025), -$7.7 million (Q3 2025), and -$2.0 million (Q2 2025), per Business Quant data.